UbiSight proteomics will provide a complete assessment of the ubiquitylation sites on all proteins in your samples. Accordingly, you can identify in the ubiquitin conjugation sites on proteins from your cell or tissue samples in response to different treatments, including siRNA knockdown, stress induction, or drug treatment. We will provide general guidance to facilitate your analysis of the raw data. UbiSight proteomics will enable the discovery of novel ubiquitylation sites on proteins from cell and tissue samples. This methodology can be applied to discover new biological regulation pathways, monitor the cellular effects of a novel drug, or identify prospective disease biomarkers.
TECHNOLOGY OVERVIEW
LifeSensors UbiSight® Technology employs proprietary methodologies from LifeSensors (LS) for qualitative and quantitative profiling of ubiquitination (Ub) sites of proteins by ubiquitin chain linkage specific separation (using TUBE) and peptide enrichment (using UbiSight antibody) followed by analysis using liquid chromatography (LC) tandem mass spectrometry (MS/MS), currently under development. These include phosphorylation status of Ub and ubiquitin chain linkage. UbiSight® Technology enables researchers to isolate, identify, and quantitate large numbers of ubiquitinated cellular peptides with a high degree of specificity and sensitivity, providing a global overview of ubiquitination in cell and tissue samples without preconceived biases.
UbiSight® technology contains two services with sequential enrichment steps: (1) TUBE-based isolation of ubiquitinated proteins from cells and tissues, and (2) UbiSight antibody pull-down of ubiquitin remnant peptides after digestion with proteases such as Lys-C or Glu-C. It allows identification and quantification of hundreds to thousands of protein targets within various cellular pathway in response to a treatment or disease state in a single LC-MS/MS run.